BR112012006501A8 - Polipeptídios e usos dos mesmos - Google Patents

Polipeptídios e usos dos mesmos

Info

Publication number
BR112012006501A8
BR112012006501A8 BR112012006501A BR112012006501A BR112012006501A8 BR 112012006501 A8 BR112012006501 A8 BR 112012006501A8 BR 112012006501 A BR112012006501 A BR 112012006501A BR 112012006501 A BR112012006501 A BR 112012006501A BR 112012006501 A8 BR112012006501 A8 BR 112012006501A8
Authority
BR
Brazil
Prior art keywords
fragment
fusion
variant
derivative
polypeptides
Prior art date
Application number
BR112012006501A
Other languages
English (en)
Other versions
BR112012006501A2 (pt
Inventor
Kalle Martina
Martin Malmsten Nils
Papareddy Praveen
Ryndengård Victoria
Schmidtchen Artur
Ulrik Walse Björn
Original Assignee
Ximmune Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ximmune Ab filed Critical Ximmune Ab
Publication of BR112012006501A2 publication Critical patent/BR112012006501A2/pt
Publication of BR112012006501A8 publication Critical patent/BR112012006501A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

POLIPEPTÍDEOS E USOS DOS MESMOS. A presente invenção fornece polipeptídeos compreendendo ou consistindo em uma sequência de aminoácido derivada de uma proteína de ocorrência natural que modula a coagulação sanguínea ou um fragmento, variante, fusão ou derivado da mesma, ou uma fusão do dito fragmento, variante ou derivado do mesmo, para uso no tratamento ou prevenção da inflamação e/ou coagulação excessiva do sangue. Os aspectos correlatos da invenção fornecem polipeptídeos isolados compreendendo ou consistindo em uma sequência de aminoácido das SEQ ID Nos: 1 a 11, ou um fragmento, variante, fusão ou derivado da mesma, ou uma fusão do dito fragmento, variante ou derivado do mesmo, que exibe uma atividade anti-inflamatória e/ou anticoagulante, em conjunto com moléculas de ácido nucléico isoladas, vetores e células hospedeiras para fabricação dos mesmos. Adicionalmente são fornecidas composições farmacêuticas compreendendo um polipeptídeo da invenção, bem como métodos de uso dos mesmos no tratamento e/ou prevenção de inflamação e/ou coagulação excessiva.
BR112012006501A 2009-09-22 2010-09-22 Polipeptídios e usos dos mesmos BR112012006501A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0916578.8A GB0916578D0 (en) 2009-09-22 2009-09-22 Polypeptides and uses thereof
PCT/GB2010/001781 WO2011036445A2 (en) 2009-09-22 2010-09-22 Polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
BR112012006501A2 BR112012006501A2 (pt) 2016-08-16
BR112012006501A8 true BR112012006501A8 (pt) 2017-07-11

Family

ID=41278086

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012006502A BR112012006502A2 (pt) 2009-09-22 2010-09-21 fragmentos de cofator ll de heparina com atividade anti-inflamatória e anticoagulante
BR112012006501A BR112012006501A8 (pt) 2009-09-22 2010-09-22 Polipeptídios e usos dos mesmos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112012006502A BR112012006502A2 (pt) 2009-09-22 2010-09-21 fragmentos de cofator ll de heparina com atividade anti-inflamatória e anticoagulante

Country Status (12)

Country Link
US (2) US9169315B2 (pt)
EP (2) EP2480244A1 (pt)
JP (2) JP2013505030A (pt)
CN (2) CN102655874B (pt)
AU (2) AU2010299630A1 (pt)
BR (2) BR112012006502A2 (pt)
CA (2) CA2774288A1 (pt)
EA (1) EA201200515A1 (pt)
GB (1) GB0916578D0 (pt)
IN (2) IN2012DN02981A (pt)
MX (1) MX2012003425A (pt)
WO (2) WO2011036444A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2748616B1 (en) * 2011-08-23 2018-08-08 Synapse B.V. Thermostable inhibitors of activation of the blood clotting system through contact with foreign surfaces.
RU2476231C1 (ru) * 2011-10-11 2013-02-27 Федеральное государственное бюджетное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации Способ купирования некроза краев кожи послеоперационной раны после эндопротезирования голеностопного сустава
GB2500184A (en) * 2012-03-12 2013-09-18 Ximmune Ab Polypeptide derived from helix A of heparin cofactor II
CN104292309B (zh) * 2014-09-29 2017-04-12 广西中医药大学 一种小分子多肽
JPWO2016104436A1 (ja) * 2014-12-22 2017-10-26 国立大学法人 岡山大学 サイトカインストーム抑制剤
RU2606836C2 (ru) * 2015-03-12 2017-01-10 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Антикоагулянтный, антитромбоцитарный и фибриндеполимеризационный комплекс на основе гепарина, способ его получения и применение
RU2610433C1 (ru) * 2016-02-17 2017-02-10 Людмила Анисимовна Ляпина Антикоагулянт
CN107875372A (zh) * 2017-12-20 2018-04-06 辽宁师范大学 重组肽rLj‑112在制备协同肝素抗凝药物中的应用
CN108338163A (zh) * 2018-03-28 2018-07-31 陈太师 一种持效型杀菌灭藻剂的制备方法
US20210198317A1 (en) * 2018-05-31 2021-07-01 National University Corporation Okayama University Reactive oxygen production inhibitor and/or scavenging promoter
US20210196787A1 (en) * 2018-06-28 2021-07-01 National University Corporation Okayama University Agent for enhancing phagocytosis ability of neutrophils
BR112021002725A2 (pt) * 2018-08-16 2021-07-20 F. Hoffmann-La Roche Ag métodos para avaliar a fibrilação atrial, para prever o risco de acidente vascular cerebral, para avaliar a eficácia de uma terapia, para identificar um paciente, para monitorar a terapia de anticoagulação e para auxiliar na avaliação da fibrilação atrial, método implementado por computador, kit e uso in vitro
CN109432513B (zh) * 2018-12-12 2021-03-23 中国医科大学 一种具有抗血栓再形成功能的生物材料及其制备方法
US11904000B2 (en) 2019-05-06 2024-02-20 Brown University Compositions and methods to enhance cutaneous wound healing
CN114364394A (zh) * 2020-05-26 2022-04-15 约翰内斯·古滕伯格美因兹大学医学院 用于治疗冠状病毒感染及相关凝血病的方法和组合物
CN114292765B (zh) * 2021-09-24 2023-04-07 江西康之康中药科技有限公司 枯草芽孢杆菌纳豆亚种r3及其在发酵水蛭低温干燥品中的应用
CN114886116B (zh) * 2022-03-18 2023-11-21 广东丸美生物技术股份有限公司 一种调理育龄女性健康的组合物及其制备方法和饮料及应用
CN116836233B (zh) * 2023-08-31 2023-11-14 中国农业大学 抗炎活性多肽及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5102995A (en) * 1989-10-20 1992-04-07 Washington University Dna encoding modified heparin cofactor ii
US5118793A (en) * 1989-10-20 1992-06-02 Washington University Modified heparin cofactor II
US5643872A (en) 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
AU1873092A (en) * 1991-04-09 1992-11-17 Brigham And Women's Hospital Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
US6008058A (en) 1993-06-18 1999-12-28 University Of Louisville Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5712247A (en) * 1995-02-21 1998-01-27 University Of North Carolina Use of lactoferrin to modulate and/or neutralize heparin activity
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JPH09176040A (ja) * 1995-12-27 1997-07-08 Green Cross Corp:The ヘパリンコファクターｉｉの医薬用途
US6946439B2 (en) * 1997-02-06 2005-09-20 Entre Med, Inc. Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments
US6207419B1 (en) * 1998-02-27 2001-03-27 The University Of North Carolina At Chapel Hill Thrombin inhibitory agents and methods of using same
AU1410801A (en) * 1999-11-17 2001-05-30 Compugen Ltd. Variants of alternative splicing
EP1469887A4 (en) * 2001-07-20 2006-01-11 Eidgenoess Tech Hochschule COMPOSITIONS AND METHODS FOR USE AS BIOACTIVE AGENTS OF SULFATED AND SULFONATED AMINO ACIDS
GB0131112D0 (en) 2001-12-31 2002-02-13 Univ London Pharmacy Block copolymers
EP1530629B1 (en) * 2002-05-31 2011-08-31 The University of Utah Research Foundation Variants of antithrombin iii
EP1567185B1 (en) * 2002-11-22 2020-02-19 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
JP2007501605A (ja) 2003-08-08 2007-02-01 ジェノバ・リミテッド 心血管疾患に関連する分泌ポリペプチド種
JP2007532486A (ja) * 2004-03-17 2007-11-15 カイロン コーポレイション 組織因子経路インヒビターの投与による重度の市中肺炎の処置
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
WO2006122139A2 (en) * 2005-05-06 2006-11-16 Novartis Ag Use of tfpi to treat severe bacterial infections
JP2009502810A (ja) * 2005-07-22 2009-01-29 ノバルティス アクチエンゲゼルシャフト 補体系と相互作用する抗微生物剤
AU2006330424B2 (en) * 2005-12-29 2013-11-14 The Regents Of The University Of California Methods and compositions related to mutant Kunitz domain I of TFPI-2
AU2006332774A1 (en) * 2005-12-29 2007-07-12 Dyax Corp. Protease inhibition
JP2009526046A (ja) * 2006-02-10 2009-07-16 デルマゲン アクティエボラーグ 新規分子
SI2147096T1 (sl) * 2007-04-13 2015-07-31 Catalyst Biosciences, Inc., Modificirani polipeptidi faktorja VII in njihove uporabe
JP2010534563A (ja) * 2007-07-24 2010-11-11 ネクスバイオ，インク． マイクロ粒子の作製のための技術

Also Published As

Publication number Publication date
US9169315B2 (en) 2015-10-27
CN102655874A (zh) 2012-09-05
CA2774296A1 (en) 2011-03-31
BR112012006502A2 (pt) 2016-08-16
JP2013505030A (ja) 2013-02-14
AU2010299631A1 (en) 2012-05-03
WO2011036445A3 (en) 2011-09-01
EA201200515A1 (ru) 2012-10-30
CN102655874B (zh) 2015-06-10
EP2480244A1 (en) 2012-08-01
US20120189673A1 (en) 2012-07-26
WO2011036445A2 (en) 2011-03-31
BR112012006501A2 (pt) 2016-08-16
CN102639556A (zh) 2012-08-15
CA2774288A1 (en) 2011-03-31
GB0916578D0 (en) 2009-10-28
MX2012003425A (es) 2012-10-09
AU2010299630A1 (en) 2012-04-26
US20120177715A1 (en) 2012-07-12
WO2011036444A1 (en) 2011-03-31
IN2012DN02981A (pt) 2015-07-31
EP2480564A2 (en) 2012-08-01
WO2011036444A4 (en) 2011-06-23
IN2012DN03368A (pt) 2015-10-23
AU2010299630A2 (en) 2012-05-03
JP2013505286A (ja) 2013-02-14

Similar Documents

Publication Publication Date Title
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
BR112014024282A2 (pt) anticorpos ligantes ao receptor b1 da bradicinina
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
BR112012009854B8 (pt) proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, método de confecção da referida proteína de ligação e uso da mesma
BR112012029588A2 (pt) materiais biológicas relacionados a her3.
BR112019001099A2 (pt) usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
BR112022016550A2 (pt) Proteínas de ligação a flt3 e métodos de uso
BRPI0614761A2 (pt) proteìnas de fusão de albumina
BRPI0806578A8 (pt) Promotores de lactococcus e usos dos mesmos
BR112014018210A2 (pt) moléculas de ácido nucleico artificiais para expressão de proteína ou peptídeo melhorada
BR112014007469A2 (pt) arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas
BR112012029577A2 (pt) polipeptídeos helicoidais randômicos prolina/alanina biossintéticos e seus usos.
BR112015013525A2 (pt) método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
BR112012018669A2 (pt) Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
BRPI0315666B8 (pt) dna de a34 e a33 do tipo 3, proteínas, seus anticorpos e métodos de tratamento usando os mesmos
BR112017020961A2 (pt) muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação
BR112013003522A8 (pt) "polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, uso, método de preparação, bem como ácido nucleico codificando os mesmos"
BRPI0720879A2 (pt) microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.
DK2010563T3 (da) Syntetisk MeCP2 sekvens til proteinsubstitutionsterapi
BR112014026162A2 (pt) Proteína de fusão ou variante da mesma, molécula de ácido nucleico, vetor de expressão, célula hospedeira, animal não humano geneticamente modificado, planta geneticamente modificada, agente terapêutico para doenças melhoradas por lactoferrina, composição farmacêutica, e, método para preparar a proteína de fusão ou variante da mesma

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B25G Requested change of headquarter approved

Owner name: XIMMUNE AB (SE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25A Requested transfer of rights approved

Owner name: XIMMUNE AB (SE)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: XIMMUNE AB (SE)

B350 Update of information on the portal [chapter 15.35 patent gazette]